AstraZeneca (AZN) Scheduled to Post Quarterly Earnings on Thursday

AstraZeneca (NASDAQ:AZN) is set to post its quarterly earnings results before the market opens on Thursday, April 25th. Analysts expect AstraZeneca to post earnings of $0.97 per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.73 earnings per share for the quarter, missing the consensus estimate of $0.74 by ($0.01). AstraZeneca had a return on equity of 30.19% and a net margin of 13.00%. The business had revenue of $12.02 billion for the quarter, compared to the consensus estimate of $12.07 billion. During the same quarter in the prior year, the company earned $0.69 earnings per share. AstraZeneca’s quarterly revenue was up 7.3% compared to the same quarter last year. On average, analysts expect AstraZeneca to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

AstraZeneca Trading Up 2.3 %

Shares of NASDAQ AZN opened at $70.13 on Tuesday. The stock has a market cap of $217.43 billion, a P/E ratio of 36.53, a price-to-earnings-growth ratio of 1.26 and a beta of 0.50. AstraZeneca has a 52-week low of $60.47 and a 52-week high of $76.56. The firm has a 50 day moving average price of $66.42 and a two-hundred day moving average price of $65.89. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.64 and a current ratio of 0.82.

AstraZeneca Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Monday, March 25th. Shareholders of record on Friday, February 23rd were given a dividend of $0.965 per share. The ex-dividend date was Thursday, February 22nd. This represents a yield of 2.3%. This is a boost from AstraZeneca’s previous Semi-Annual dividend of $0.47. AstraZeneca’s dividend payout ratio is 100.52%.

Wall Street Analyst Weigh In

A number of research firms recently commented on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. Morgan Stanley initiated coverage on AstraZeneca in a report on Tuesday, January 23rd. They set an “overweight” rating for the company. Finally, Jefferies Financial Group cut AstraZeneca from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus price target of $80.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.